From: The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients
Name | Description | Deterministic value | Probabilistic components | Source | |||||
---|---|---|---|---|---|---|---|---|---|
Distribution | Range | Gamma | Alpha1 | Alpha 2 | |||||
Min | Max | ||||||||
cDR | Cost discount rate | 0.035 | Fixed | Pharmaco economic guidelines (NICE) | |||||
oDR | Outcome discount rate | 0.035 | Fixed | Pharmaco economic guidelines (NICE) | |||||
cArgus II | Costs of device + implantation | 90800 | BETA Pert | 68100 | 113500 | 8 | 5 | 5 | Second Sight |
cRP | Annual health care costs incurred on RP patients | 11789 | BETA Pert | 8841 | 14736 | 8 | 5 | 5 | Frick et al. [14] |
cVA+ | Annual health care costs incurred on RP patients with VA+ | 9431 | BETA Pert | 7073 | 11789 | 8 | 5 | 5 | Frick et al. [14] + assumption |
cVA++ | Annual health care costs incurred on RP patients with VA++ | 8252 | BETA Pert | 6189 | 10315 | 8 | 5 | 5 | Frick et al. [14]+ assumption |
cVA+++ | Annual health care costs incurred on RP patients with VA+++ | 7073 | BETA Pert | 5305 | 8841 | 8 | 5 | 5 | Frick et al. [14] + assumption |
cSAE | Cost of management of Serious Adverse Event | 1000 | BETA Pert | 750 | 1250 | 8 | 5 | 5 | Expert opinion |
cExplant | Cost of Explantation | 2000 | BETA Pert | 1500 | 2500 | 8 | 5 | 5 | Humayun et al. [9]/Second sight |
cOthers | Annual other costs for Argus II patients (e.g. Upgrades etc.) | 300 | BETA Pert | 225 | 375 | 8 | 5 | 5 | Humayun et al. [9]/Second sight |
pVA+ | Argus II patient’s annual probability of getting VA+ | 0.74 | BETA Pert | 0.554 | 0.924 | 8 | 5 | 5 | Humayun et al. [9]/Second Sight |
pVA++ | Argus II patient’s annual probability of getting VA++ | 0.21 | BETA Pert | 0.154 | 0.257 | 8 | 5 | 5 | Humayun et al. [9]/Second sight |
pVA+++ | Argus II patient’s annual probability of getting VA++ | 0.04 | BETA Pert | 0.029 | 0.049 | 8 | 5 | 5 | Humayun et al. [9]/Second sight |
pSAE | Probability of Serious Adverse Event in Argus II patients in first year | 0.3 | BETA Pert | 0.225 | 0.375 | 8 | 5 | 5 | Humayun et al. [9]/Second Sight |
pExplant | Argus II patient’s annual probability of device explantation | 0.02 | BETA Pert | 0.013 | 0.021 | 8 | 5 | 5 | Humayun et al. [9]/Second Sight |
uRP | Utility value in RP patients | 0.26 | BETA Pert | 0.195 | 0.325 | 8 | 5 | 5 | Brown et al. [18] |
uVA+ | Utility value in RP patients with VA+ | 0.35 | BETA Pert | 0.263 | 0.438 | 8 | 5 | 5 | Brown et al. [18] |
uVA++ | Utility value in RP patients with VA++ | 0.52 | BETA Pert | 0.39 | 0.65 | 8 | 5 | 5 | Brown et al. [18] |
uVA+++ | Utility value in RP patients with VA+++ | 0.54 | BETA Pert | 0.405 | 0.675 | 8 | 5 | 5 | Brown et al. [18] |
uSAE | (dis) utility value in patients with Serious Adverse Events | 0.16 | BETA Pert | 0.12 | 0.2 | 8 | 5 | 5 | Schiffman et al. [19] |
uExplant | Utility value in patients post Argus II explantation | 0.26 | BETA Pert | 0.195 | 0.325 | 8 | 5 | 5 | Assumption |